Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials.
The mean and median ages of diagnosis of multiple myeloma range from 70 to 73 years old, with 63% of patients being over the age of 65. Phase 3 clinical trials are designed to study efficacy in the target disease population and are meant to have the most representative subject pool. The purpose of t...
| Publicado en: | Journal of Oncology Pharmacy Practice Vol. 26; no. 6; pp. 1475 - 1482 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Sep2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |